EICHORPublic-registry site landscape for NCT02793583, “Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma”, a Diffuse Large B-Cell Lymphoma study sponsored by TG Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02793583 (registry record) |
| Study title | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma |
| Official title | A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma |
| Sponsor | TG Therapeutics, Inc. |
| Condition(s) | Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma |
| Phase | PHASE2 / PHASE3 |
| Listed sites | 168 |
| Site countries | United States, Australia, Israel, Italy, Poland, Slovakia, South Korea, Spain, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT02793583.
Eichor generates a preliminary site-risk snapshot for NCT02793583 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Diffuse Large B-Cell Lymphoma trials
More from TG Therapeutics, Inc.
← Eichor home · All tracked trials · Diffuse Large B-Cell Lymphoma studies · Weekly briefs
